Last edited by Vuzil
Monday, August 3, 2020 | History

2 edition of Pharmaceutical innovation, mortality reduction, and economic growth found in the catalog.

Pharmaceutical innovation, mortality reduction, and economic growth

Frank R. Lichtenberg

Pharmaceutical innovation, mortality reduction, and economic growth

by Frank R. Lichtenberg

  • 290 Want to read
  • 18 Currently reading

Published by National Bureau of Economic Research in Cambridge, MA .
Written in English

    Subjects:
  • Pharmaceutical industry -- Technological innovations -- United States -- Econometric models.,
  • Drugs -- Effectiveness -- United States -- Econometric models.,
  • Drugs -- Research -- United States -- Econometric models.,
  • Life expectancy -- United States -- Econometric models.

  • Edition Notes

    StatementFrank R. Lichtenberg.
    SeriesNBER working paper series -- working paper 6569, Working paper series (National Bureau of Economic Research) -- working paper no. 6569.
    ContributionsNational Bureau of Economic Research.
    Classifications
    LC ClassificationsHB1 .W654 no. 6569
    The Physical Object
    Pagination28 p. :
    Number of Pages28
    ID Numbers
    Open LibraryOL22403059M

    This book explores four important issues in pharmaceutical innovations: (1) the industry structure of pharmaceutical innovation; (2) incentives for correcting market failures in allocating resources for research and development; (3) competition and marketing; and (4) public evaluation of the benefits and costs of innovation. Mark Duggan and Fiona Scott Morton (), 'The Effect of Medicare Part D on Pharmaceutical Prices and Utilization' Frank R. Lichtenberg (), 'Pharmaceutical Innovation, Mortality Reduction, and Economic Growth' Bernard Munos (), 'Lessons from 60 Years of Pharmaceutical Innovation' C The Generic Drug Industry

    Pandemics are large-scale outbreaks of infectious disease that can greatly increase morbidity and mortality over a wide geographic area and cause significant economic, social, and political disruption. Evidence suggests that the likelihood of pandemics has increased over the past century because of increased global travel and integration, urbanization, changes in land use, Cited by: 4. E-book $ to $ About E-books ISBN: Published April In , health expenditures in the United States accounted for % of national income-the highest share of income devoted to health in the developed world.

    Pharmaceutical Innovation, Mortality Reduction, and Economic Growth By Frank R. LichtenbergCited by: 9.   In this paper, I will analyse the effect that pharmaceutical innovation had on premature mortality from all diseases in Australia during the period – This period was chosen because a consistent cause‐of‐death classification (ICD‐10) was used in these years. In essence, I will investigate whether the diseases that experienced more pharmaceutical innovation Cited by: 5.


Share this book
You might also like
Echoes of the Holocaust

Echoes of the Holocaust

Moving with children

Moving with children

Francis Bacon, recent paintings

Francis Bacon, recent paintings

From the stage to the studio

From the stage to the studio

tragedy of Patrick Branwell Brontë.

tragedy of Patrick Branwell Brontë.

Early clockmaking in Connecticut.

Early clockmaking in Connecticut.

Notes on the bacteriological study of diphtheria

Notes on the bacteriological study of diphtheria

Cloze connections

Cloze connections

Review of VISTA by representatives of national organizations

Review of VISTA by representatives of national organizations

Examining the value of, and possible content for global citizenship curriculum for junior students

Examining the value of, and possible content for global citizenship curriculum for junior students

Taxation in Italy

Taxation in Italy

Pharmaceutical innovation, mortality reduction, and economic growth by Frank R. Lichtenberg Download PDF EPUB FB2

The estimates imply that in the absence of pharmaceutical innovation, there would have been no increase and perhaps even a small decrease in mean age at death, and that new drugs have increased life expectancy, and lifetime income, by about % per annum.

Pharmaceutical Innovation, Mortality Reduction, and Economic Growth Pharmaceutical Innovation, Mortality Reduction, and Economic Growth Chapter: (p) Chapter Three Pharmaceutical Innovation, Mortality Reduction, and Economic Growth Source: Measuring the Gains from Medical Research Author(s): Frank R.

Lichtenberg Publisher: University of. We perform an econometric investigation of the contribution of pharmaceutical innovation to mortality reduction and growth in lifetime per capita : Frank Lichtenberg. We investigate econometrically whether the increase in longevity (which may constitute half of economic growth, broadly defined) can be explained by a certain kind of technological progress--the development and diffusion of new drugs--by analyzing the relationship across diseases between the long-term reduction in life-years lost before age 75 and the relative utilization of new pharmaceutical products.

"Pharmaceutical Innovation, Mortality Reduction, and Economic Growth." NBER Working Paper W, National Bureau of Economic Research, May Each author name for a Columbia Business School faculty member is linked to a faculty research page, which lists additional publications by that faculty member.

Frank R. Lichtenberg (), 'Pharmaceutical Innovation, Mortality Reduction, and Economic Growth' Bernard Munos (), 'Lessons from 60 Years of Pharmaceutical Innovation' C The Generic Drug Industry Richard E.

Caves, Michael D. Whinston and Mark A. Hurwitz (), 'Patent Expiration, Entry, and Competition in the U.S.

Pharmaceutical. Leading Pharmaceutical Innovation: Trends and Drivers for Growth in the Pharmaceutical Industry Softcover reprint of hardcover 2nd ed. Edition. by Oliver Gassmann (Author) › Visit Amazon's Oliver Gassmann Page. Find all the books, read about the author, and more. Cited by: F. Lichtenberg, The contribution of pharmaceutical innovation to 5 longevity growth in Germany and France, Pharmacoeconomics (In press) New treatments reduced mortality rates in Canada Introduction of the new treatments in the lastIntroduction of the new treatments in the last three decades reduced the risk of mortality by.

Pharmaceutical innovation is estimated to have accounted for almost three-fourths of the year increase in life expectancy at birth in the 30 countries in our sample.

Pharmaceutical Innovation, Mortality Reduction and Economic Growth,” NBER Working Paper: (which may constitute half of economic growth, broadly defined) can be explained by a certain kind of technological progress--the development and diffusion of new drugs--by analyzing the relationship across diseases between the long-term Author: Frank R.

Lichtenberg. The Societal Value of Pharmaceutical Innovation. Abstract. Drug innovation has had a profound effect on people, resulting in extended longevity and better quality of life, though development of new drugs has become expensive, with estimates ranging from $1 billion to $4 billion to $11 : Vijay Kumar, R.

Sundarraj. It is, therefore, difficult to separate the influence of economic growth and the advancement of medical technology. Nevertheless, we were able to demonstrate the influence of innovation apart from economic growth, and further investigations of this sort may help to shed light on the common antecedents of economic growth and mortality by: Get this from a library.

Pharmaceutical innovation, mortality reduction, and economic growth. [Frank R Lichtenberg; National Bureau of Economic Research.] -- Abstract: We perform an econometric investigation of the contribution of pharmaceutical innovation to mortality reduction and growth in lifetime per capita income.

In both of the periods studied. Pharmaceutical Innovation, Mortality Reduction, and Economic Growth. drugs. The estimates imply that in the absence of pharmaceutical innovation, there would have been no increase and perhaps even a small decrease in mean age at death, and that new drugs have increased life expectancy, and lifetime income, by about % per annum Author: Frank R.

Lichtenberg. 9. Mark Duggan and Fiona Scott Morton (), ‘The Effect of Medicare Part D on Pharmaceutical Prices and Utilization’ Frank R. Lichtenberg (), ‘Pharmaceutical Innovation, Mortality Reduction, and Economic Growth’ Bernard Munos (), ‘Lessons from 60 Years of Pharmaceutical Innovation’ C The Generic Drug Industry Pages: The pharmaceutical industry has encountered a period of dramatic structural change.

The first manifestation has been a productivity shock, as the number of new molecular entities approved for introduction into the United States market between and grew only slightly despite an increase in inflation-adjusted research and development expenditures at a rate of roughly Cited by: "The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality," NBER Working PapersNational Bureau of Economic Research, Inc.

Frank R. Lichtenberg, "Pharmaceutical Innovation, Mortality Reduction, and Economic Growth," NBER Working PapersNational Bureau of Economic Research, Inc. The Economics of Pharmaceutical Pricing Wayne Winegarden, Ph.D. Senior Fellow, Pacific Research Institute average growth rate in the S&P between and ( percent), then over 15 years, every There are many risks associated with pharmaceutical innovation.

There are the risks that the poten-File Size: KB. Mark Duggan and Fiona Scott Morton (), ‘The Effect of Medicare Part D on Pharmaceutical Prices and Utilization’ Frank R.

Lichtenberg (), ‘Pharmaceutical Innovation, Mortality Reduction, and Economic Growth’ Bernard Munos (), ‘Lessons from 60 Years of Pharmaceutical Innovation’ C The Generic Drug Industry The most widely-used measure of medical progress is the growth in life expectancy.

Life expectancy (E) in selected years since is shown below: 54 70 74 76 The average person born in expects to live 22. This article, written for the forthcoming Handbook of the Economics of Technical Change, surveys the costs, risks, and challenges encountered in the discovery a Pharmaceutical Innovation, Mortality Reduction, and Economic Growth The Cost of Us Pharmaceutical Price Reductions: A Financial Simulation Model of R&D Decisions.for example, “Pharmaceutical Innovation, Mortality Reduction, and Economic Growth,” in Measuring the Gains from Medical Research: An Economic Approach, ed.

by Kevin M. Murphy and Robert H. Topel (Chicago: University of Chicago Press, ), pp. ; “Sources of U.S. Longevity Increase, (Robert R.

Rothberg, Journal of Product Innovation Management, Vol. 22, ) From the reviews of the second edition: “Leading Pharmaceutical Innovation, Gassmann and colleagues describe the current status of the pharmaceutical industry.

This book comprises seven chapters, where each could be seen as a review of the addressed topic.